Atlas Trials

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

Clinical trial NCT04231370 · UNKNOWN

Trial details

NCT number
NCT04231370
Sponsor
Beijing Tongren Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
NK/T Cell Lymphoma Nos
Start date
2020-04-01
Primary completion
2022-02-28
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.